Business Context and Reporting Period
Company: SelectQuote, Inc. (SLQT)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three and six months ended December 31, 2025 (Fiscal Year 2026 Q2)
Business Overview: SelectQuote is a technology-enabled direct-to-consumer distribution platform for insurance (Senior, Life, Auto & Home) and healthcare services (SelectRx pharmacy, chronic care management). The company operates three reportable segments: Senior, Healthcare Services, and Life.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Dec 31, 2025 | 6 Months Ended Dec 31, 2025 | 6 Months Ended Dec 31, 2024 |
|---|---|---|---|
| Total Revenue | $537,102 | $865,913 | $773,332 |
| Net Income | $69,293 | $38,834 | $8,690 |
| Net Income Attributable to Common Shareholders | $51,168 | $3,227 | $8,690 |
| Income from Operations | $75,311 | $34,565 | $58,962 |
| Adjusted EBITDA | $84,731 | $52,652 | $85,835 |
| Cash, Cash Equivalents, and Restricted Cash | $22,201 (Current) | $23,338 (Total) | $37,066 (Total) |
| Total Debt (Gross) | $405,796 | $405,796 | $385,112 |
| Operating Cash Flow | Not provided for 3 months | $(21,571) | $(45,304) |
Note: Net Income Attributable to Common Shareholders is significantly reduced by Senior Non-Convertible Preferred Stock dividends and accretion ($35.6 million for the six months ended Dec 31, 2025).
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 12% year-over-year for both the three and six-month periods. This was driven primarily by a 26% (Q2) and 34% (YTD) increase in Pharmacy revenue due to a 17% growth in SelectRx members.
- Segment Performance:
- Healthcare Services: Revenue surged to $230.7M (Q2) and $452.0M (YTD), though Adjusted EBITDA remained low ($0.8M Q2, $8.1M YTD) due to high cost of goods sold (medication costs).
- Senior: Revenue was flat Q2 (+2%) but declined YTD (-8%) due to a 5% decrease in approved policies and lower Lifetime Value (LTV) per policy.
- Life: Revenue increased 9% (Q2) and 14% (YTD), driven by a 24% increase in final expense premiums.
- Profitability: Net income attributable to common shareholders dropped significantly on a YTD basis ($3.2M vs $8.7M prior year) due to the accretion and dividends on the Senior Non-Convertible Preferred Stock issued in February 2025.
- Interest Expense: Interest expense decreased 50% YTD ($23.4M vs $46.8M) following the repayment of $260M in Term Loans using proceeds from the Preferred Stock issuance.
- Warrant Liability: A non-cash gain of $34.3M was recognized on the change in fair value of warrant liabilities, significantly boosting Net Income.
Guidance, Outlook, Risks, and Unusual Items
- Subsequent Event (Refinancing): On January 8, 2026, the company entered into a new $415M credit agreement ($325M Term Loan, $90M Revolver) maturing in 2031. Proceeds were used to repay all outstanding amounts under the previous Senior Secured Credit Facility. The company expects to recognize a loss on extinguishment of approximately $8.7M in Q3 FY2026.
- Legal Proceedings:
- DOJ Action: The U.S. Attorney's Office intervened in a qui tam action alleging violations of the False Claims Act regarding sales practices. The company denies allegations and is defending vigorously.
- Securities Litigation: An appeal regarding a securities class action is pending before the Second Circuit, with oral arguments scheduled for February 27, 2026.
- Seasonality: The Senior segment is highly seasonal, with revenue peaking during the Medicare Annual Enrollment Period (October–December). This impacts working capital and cash flow timing.
- Preferred Stock: The company has $350M of Senior Non-Convertible Preferred Stock outstanding with a 14.5% annual dividend rate (accruing and compounding if not paid in cash). This instrument ranks senior to common stock and significantly impacts earnings available to common shareholders.
Investor Verification Checklist
- Preferred Stock Impact: Verify the cash flow impact of the 14.5% dividend on the $350M Preferred Stock and the accretion charges reducing common equity earnings.
- Refinancing Loss: Monitor the Q3 FY2026 financials for the expected $8.7M loss on debt extinguishment related to the January 2026 refinancing.
- Legal Exposure: Track the status of the DOJ qui tam action and the securities class action appeal, as unfavorable outcomes could result in significant liabilities.
- Pharmacy Margins: Assess the sustainability of Healthcare Services margins given the rapid growth in SelectRx members and the associated increase in medication costs (COGS).
- Warrant Liability Volatility: Note that Net Income is heavily influenced by the non-cash mark-to-market adjustment of warrant liabilities, which fluctuates with the company's stock price.